3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Colorectal Neoplasms
2
Thyroid Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Magnetic Resonance Spectroscopy
5
trametinib
4
pembrolizumab
4
Trastuzumab
3
Nivolumab
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
larotrectinib
2
belinostat
2
Surveys and Questionnaires
2
Sunitinib
2
Specimen Handling
2
Radiosurgery
2
Gemcitabine
2
Fluorodeoxyglucose F18
2
FAPI-46
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
tislelizumab
1
spartalizumab
1
sargramostim
1
sapanisertib
1
romidepsin
1
repotrectinib
1
relatlimab
1
regorafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
naporafenib
×
Gastrointestinal
×
Clear all
NCT05907304
2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1
Active not recruiting
86 enrolled